A 1-Year Safety Study of Dulaglutide in Japanese Patients With Type 2 Diabetes on a Single Oral Hypoglycemic Agent: An Open-Label, Nonrandomized, Phase 3 Trial

Endocrine Journal - Japan
doi 10.1507/endocrj.ej15-0401
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japan Endocrine Society


Related search